Takeda的AI设计的药物Zasocitinib在试验中取得了显著成果,增加了其库存,并为2027年美国发射铺平了道路。 Takeda's AI-designed drug zasocitinib showed strong results in trials, boosting its stock and paving the way for a 2027 U.S. launch.

Takeda制药公司在2025年12月16日东京早期交易中的份额上升了4.3%,在实验性口服药物Zasocitinib实验性口服药物在对中度至重度白丝虫病的第三阶段试验中显示出强有力的成果后,达到三个月的最高水平。 Takeda Pharmaceuticals shares rose 4.3% in early Tokyo trading on December 16, 2025, reaching a three-month high, after its experimental oral drug zasocitinib showed strong results in Phase 3 trials for moderate to severe plaque psoriasis. 该药物每天服用一次,导致超过半数患者在16周后完成或几乎完全清除了皮肤损伤,超过现有治疗水平。 The drug, taken once daily, led to complete or near-complete clearance of skin lesions in over half of patients after 16 weeks, outperforming existing treatments. Takeda计划在2026财政年度提交美国林业发展局的申请,可能于2027年3月启动。 Takeda plans to submit a U.S. FDA application in fiscal 2026, with a potential launch in March 2027. 分析家称结果为“最优级”, 预计高峰销售额为1500亿日元(9.64亿美元)。 Analysts called the results "best-in-class," with projected peak sales of 150 billion yen ($964 million). 该药物是使用AI研制的,2023年以40亿美元获得,可能是AI首次批准的药物之一。 The drug, developed using AI and acquired for $4 billion in 2023, could be among the first AI-designed drugs approved.